I am preparing to start an off-label protocol using the SGLT-2 inhibitor empagliflozin (Jardiance) for its metabolic optimization and downstream metabolic pathways. Given the compelling NIA Interventions Testing Program (ITP) data on SGLT-2 inhibitors and their systemic effects on nutrient sensing, I am eager to integrate this into my regimen.
However, I want to calibrate my approach using real-world data from like-minded non-diabetic peers who have already blazed this trail. As you understand, we want to avoid common pitfalls and optimize our baseline variables.
If you are a non-diabetic currently utilizing or experimenting with empagliflozin, I would highly appreciate your insights:
- Did you begin directly at 10mg, or did you micro-dose/titrate upward? What is your current maintenance dose and timing (e.g., morning vs. pre-workout)?
- Are you stacking empagliflozin with other interventions like OMAD, Metformin, Berberine, or GLP-1 agonists? If so, have you noticed any synergistic or antagonistic effects on your glycemic profile?
- What objective changes did you track via blood work or continuous glucose monitoring (CGM) regarding fasting blood glucose, HbA1c, fasting insulin, or baseline ketone levels?
- How do you manage the persistent renal glucose/fluid drain? Specifically, what is your electrolyte protocol to prevent dehydration, and how do you navigate exercise performance or fasting windows without risking DKA (Ketoacidosis)?

